Trial Profile
An open-label study in healthy subjects and in patients with stable impaired renal function to assess the effect of severe renal impairment on licarbazepine pharmacokinetics and metabolism after the single administration of a 500 mg licarbazepine immediate release (IR) tablet
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 17 Feb 2007
Price :
$35
*
At a glance
- Drugs Licarbazepine (Primary)
- Indications Bipolar disorders
- Focus Pharmacokinetics
- Sponsors Novartis
- 17 Feb 2007 New trial record.